The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint.
Ramon Salazar
Honoraria - Agendia
John Marshall
Honoraria - Agendia
Jaume Capdevila
No relevant relationships to disclose
Bengt Glimelius
No relevant relationships to disclose
Jan Willem de Waard
No relevant relationships to disclose
Jacobus Van Der Hoeven
No relevant relationships to disclose
Joost Klaase
No relevant relationships to disclose
Frédéric Bibeau
No relevant relationships to disclose
Thomas Bachleitner-Hofmann
No relevant relationships to disclose
Rachel A Midgley
No relevant relationships to disclose
Edward Allen Levine
No relevant relationships to disclose
Wai Lun Law
No relevant relationships to disclose
Michio Asano
No relevant relationships to disclose
George J. Chang
No relevant relationships to disclose
Stephen M Cohen
Honoraria - Agendia
Robert W. Beart
No relevant relationships to disclose
Paul M. Goldfarb
Honoraria - Agendia
Martin McCarter
No relevant relationships to disclose
Lisette Stork-Sloots
Employment or Leadership Position - Agendia
Robert Rosenberg
No relevant relationships to disclose